Specialized Hospital for Active Treatment of Oncology Diseases Prof. d-r Marin Mushmov EOOD
- Address
- lock Available on a paid plan
Prof. d-r Marin Mushmov Specialized Oncology Hospital
The Specialized Hospital for Active Treatment of Oncology Diseases Prof. d-r Marin Mushmov EOOD is a leading Bulgarian institution dedicated to advancing cancer care through cutting-edge clinical research. The center specializes in evaluating novel therapeutic approaches for various malignancies, with particular emphasis on hormone-receptor-positive cancers and extended adjuvant treatment strategies.
- Breast cancer endocrine therapy and adjuvant treatment optimization
- ER-positive/HER2-negative early-stage breast cancer management
- Novel selective estrogen receptor degraders and targeted therapies
The hospital's research portfolio focuses on improving long-term outcomes for breast cancer patients through extended adjuvant endocrine-based therapy. Their participation in international studies evaluating next-generation agents like camizestrant demonstrates their commitment to preventing cancer recurrence and enhancing survival rates in patients with hormone receptor-positive breast cancer. This expertise positions the center at the forefront of personalized oncology treatment strategies in Southeastern Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specialized Hospital for Active Treatment of Oncology Diseases Prof. d-r Marin Mushmov EOOD
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 2 | Unknown | 2023-09-13 | 2023-09-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.